ArticleBMC cancer2026
Sesquiterpenoids target IFIT family proteins and LIMK1: potential implications for the tumor microenvironment and macrophage infiltration.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a clinical nomogram for predicting hemorrhagic rupture in renal angiomyolipoma and analysis of molecular correlates (Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSesquiterpenoids and their derivatives have exhibited promising inhibitory effects against various types of cancers. However, the precise molecular targets and their interplay with the tumor microenvironment (TME) remain elusive.
methodsTranscriptomic data from GEO (kidney cancer, colon cancer, and acute myeloid leukemia) were analyzed to identify differentially expressed genes (DEGs) induced by sesquiterpenoids. Robust hub genes were identified using multiple algorithms (e.g., MCC) and validated using TCGA and GTEx datasets. The association between these hub genes and immune cell infiltration was evaluated via ssGSEA.
resultsThe study identified the IFIT family, LIMK1, and HERC6 as key hub genes associated with sesquiterpenoid treatment. Single-cell RNA-seq analysis suggested these genes are predominantly enriched in mononuclear macrophages within the TME. Experimental validation confirmed that Sesquiterpenoids (Costunolide) inhibited the proliferation and migration of SW480 and A-498 cancer cells in a dose-dependent manner. Furthermore, Costunolide treatment upregulated IFN-γ and modulated LIMK1 expression and phosphorylation.
conclusionThis study highlights IFIT proteins and LIMK1 as potential targets of sesquiterpenoids. These findings provide insights into how sesquiterpenoids might influence cancer progression and correlate with macrophage infiltration, suggesting their potential as therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.